e.g. mhealth
Search Results (1 to 5 of 5 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Cancer
- 1 JMIR Bioinformatics and Biotechnology
- 1 JMIR Dermatology
- 1 JMIR Perioperative Medicine
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Primary cutaneous EHE is rare and should prompt suspicion of metastatic disease, especially if multifocal in the skin [4]. Owing to their rarity and similarities to other diagnoses, cutaneous EHE lesions are commonly misdiagnosed [5]. Previous studies suggest the diagnosis of strictly cutaneous EHE incurs a 17% mortality rate at 3 years, highlighting its relatively aggressive nature [6].
JMIR Dermatol 2024;7:e52493
Download Citation: END BibTex RIS
The TCGA data set contains samples from 18 different cancer types representing 9648 samples, of which 365 were metastatic, 633 were solid normal, and 8650 were from the primary tumor site. Each sample consisted of micro RNA expression data, available as RPM (reads per million mapped reads), as well as metadata including age and gender. We split TCGA data set into a combined primary tumor or solid normal samples training set and a metastatic sample test set.
JMIR Bioinform Biotech 2024;5:e56538
Download Citation: END BibTex RIS
Participants had metastatic hormone-sensitive prostate cancer if recruited from UCSF; we allowed participants in the community to have metastatic or nonmetastatic hormone-sensitive prostate cancer and did not verify metastasis status for these participants. Any man with any self-reported cognitive or neurologic condition that, in the opinion of the study team, would prohibit the ability to read and navigate the internet or follow a diet or exercise prescription independently were excluded.
JMIR Cancer 2023;9:e45432
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Surgery, while effective for early stages of melanoma, is a less effective treatment option for patients with metastatic or late-stage disease [7]. Newer therapies such as immunotherapy treatments and targeted therapies (TTs) have shown good efficacy in the treatment of metastatic melanoma and have shifted the treatment paradigm [8,9]. TTs block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, spread, and progression of cancer.
JMIR Cancer 2022;8(2):e34073
Download Citation: END BibTex RIS